Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05044611
Other study ID # APHP200042
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 11, 2023
Est. completion date November 11, 2025

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact VRTOVSNIK Francois, Pr
Phone 01 40 25 71 01
Email francois.vrtovsnik@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lithium (Li) is the leading treatment for BD, protecting against both maniac and depressive relapse, and reducing the risk of suicide and mortality. However, despite this major clinical efficacy, the use of lithium is limited by its narrow therapeutic index and by its side effects. Li induces a vasopressin-resistant urinary concentration defect, with resulting nephrogenic diabetes insipidus (NDI) in 12-50 % of patients. This feature is more frequent after 5 years of treatment with lithium. Polyuria and subsequent thirst might affect patients' quality of life, but also cause potentially life-threatening hypernatremia if free access to water is impaired. Thus, we aim at evaluating the efficacy of amiloride on urine concentrating ability in patients with nephrogenic diabetes insipidus due to chronic lithium treatment.


Description:

Patients will be referred to the nephrology or the renal physiology department for the usual follow-up of the lithium treatment. After verification of eligilibity criteria, information and collection of consent, patient will be randomized. During the first phase, patients will be randomized in two parallel groups: the experimental arm will receive 5mg of amiloride twice daily during 2 months and the control arm will receive a placebo twice daily during 2 months. Measures of fasting urine osmolality will be performed at baseline, 2 months, at 6 months and at 12 months, in order to compare the difference of urine osmolality before and after treatment between the two-randomization arms. Other baseline explorations are as follows: mean number of nocturnal voids, SF-36 questionnaire, thirst intensity and distress scales, YMRS/MADRS mood scale, GAD7 anxiety scale, PSQI sleep scale, GFR measurement and estimation, 24h urine for the quantification of the polyuria and osmolality, plasma and erythrocyte lithium level, serum osmolality, natremia, kaliemia, urea, chlore level, complete blood count, plasma copeptine and vasopressin. A nephrologist visit will take place 15 days after the initiation of the treatment along with a new measure of plasma lithium level. Patients will be evaluated at 1 month only if a change in posology is required after the first measurement at day 15 and then at 2, 6 and 12 months. In parallel, patients will be evaluated by at the psychiatry clinic at 1 month, 2, 6 and 12 months, and in any condition requiring additional visit as usual in standard care (follow-up of anxiety, sleepiness, suicidal ideation, depression). After the completion of this first phase, the open label second phase will begin. Unblinding the trial will allow the treatment allocation being available for the participants and health care professionals. Amiloride will be continued in participants in the experimental group, and the remaining participants will be followed-up without treatment. This phase will last for 10 months (total trial duration: 12 months). At one year, renal functions (GFR, urine concentration and 24h urine production) will be assessed along with report of events including hospital admission. The safety of the experimental treatment will be assessed by regular evaluations of plasma lithium and potassium level, beginning at 2 weeks after treatment initiation and after 2 months. The main risk of amiloride is hyperkalemia, which occurs in patients with severe renal insufficiency. These patients will not be included in our study. Otherwise, the treatment is generally safe and well-tolerated. Plasma lithium level will be measured at the first month clinical evaluation if a change in posology is required after the first measurement at day 15.


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date November 11, 2025
Est. primary completion date January 11, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Adults between 18 and 70 years (age = 18 years and <70 years) - Patient with bipolar disorder - Patient treated with lithium for at least 5 years - Patient with a urine concentration defect defined by a maximal urine osmolality < 600 mOsm/kg - Woman of childbearing age agreeing to use an efficient contraceptive method for 12 months Exclusion Criteria: - Renal failure defined as eGFR < 30 ml/min/1.73m² estimated by the CKD-EPI equation - Kalemia > 5 mmol/l - Hypersensitivity or known allergy to amiloride - Hypersensitivity to lactose - Known adrenal insufficiency - Concomitant use of other potassium-sparing treatment (e.g. spironolactone, angiotensin converting enzyme inhibitors (ACE), angiotensin II receptor (AT2R) antagonists, calcineurin inhibitors tacrolimus and ciclosporin) - Acute ongoing infection (less than 3 days before inclusion) - Severe heart failure (NYHA > II) - Rhythm, conduction or repolarisation disorder present on an ECG done within 12 months prior to inclusion - Acute phase of mood disorder - Uncontrolled diabetes mellitus or diabetes with hyporeninism hypoaldosteronism - Potassium supplements - Use of heparins - Use of trimethoprim - Cirrhosis - Oedemas - Previous use of amiloride use in the 6 months prior to randomisation) - Pregnant or breastfeeding women - Participation in another clinical study involving investigational medicinal product or patient being in the exclusion period at the end of a previous study - Patient refusal to participate - Non-affiliation to a social security regimen or CMU - Patient under State Medical Aid - Subject deprived of freedom, subject under a legal protective measure

Study Design


Intervention

Drug:
Anhydrous Amiloride Hydrochloride
Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI. Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase
Placebo
Route of administration : oral the control arm will receive a placebo twice daily during 2 months

Locations

Country Name City State
France Néphrologie, Hôpital Henri-Mondor Créteil
France Néphrologie, Hopital Bichat Paris
France Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The main objective of this study is demonstrating the efficacy of amiloride to reduce the urine concentration defect in patients treated by lithium and presenting a nephrogenic diabetes insipidus after 2 months of treatment. The primary endpoint is the percentage change in maximal urine osmolality before and after 2 months of treatment 2 month after randomization
Secondary Demonstrate the efficacy of amiloride to reduce nocturia Difference in mean number of nocturnal voids 2 months after randomization and 12 months after randomization
Secondary Demonstrate the efficacy of amiloride to reduce the sensation of thirst Difference in mean number of nocturnal voids 2 months after randomization and 12 months after randomization
Secondary Demonstrate the efficacy of amiloride to reduce polyuria Presence of polyuria (defined as a daily urine output > 3 L/day) 2 months after randomization and 12 months after randomization
Secondary Demonstrate the efficacy of amiloride to increase quality of life Difference in Quality-of-life scale score (SF36) 2 months after randomization and 12 months after randomization
Secondary Demonstrate the efficacy of amiloride to reduce the decline of eGFR after one year of treatment Difference in eGFR (estimated by the CKD-EPI equation based on standardized serum creatinine measurement) before and after 12 months of treatment 12 months after randomization
Secondary Evaluate the effect of amiloride in mood stability Difference in Mood Scale scores YMRS 2 months after randomization and 12 months after randomization
Secondary Evaluate the effect of amiloride in circulating lithium levels stability Difference in residual plasma lithium levels before and after the 2 months treatment period 2 months after randomization
Secondary Evaluate the effect of amiloride in mood stability Total number of hospital admission for maniac or depressive relapse during 12 months of treatment 12 months after randomization
Secondary Evaluate the effect of amiloride in mood stability Difference in Mood Scale MADRS 2 months after randomization and 12 months after randomization
Secondary Evaluate the effect of amiloride in mood stability Difference in anxiety scale score (GAD7) 2 months after randomization and 12 months after randomization
Secondary Evaluate the effect of amiloride in mood stability Difference in the Pittsburgh sleep score (PSQI) 2 months after randomization and 12 months after randomization
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study